Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report) and keeping the price target at €10.00.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight the potential of Nanobiotix’s NBTXR3 treatment. The positive data from the Phase 1 study, which showed a significant survival benefit for patients with locally advanced pancreatic cancer, underscores the promise of NBTXR3. Patients treated with this therapy experienced a median overall survival of 23 months, which is notably higher than historical controls. Additionally, the normalization of cancer antigen 19-9 in a significant portion of patients treated with NBTXR3 suggests better survival outcomes.
Furthermore, the treatment demonstrated a favorable safety profile with no dose-limiting toxicities reported, and the ongoing evaluation of NBTXR3 in combination with standard chemoradiation could enhance its therapeutic potential. The valuation of Nanobiotix is supported by a risk-adjusted net present value analysis, leading to a 12-month price target of €10.00. Despite potential risks such as clinical and commercial challenges, the promising data and potential collaborations, such as with Johnson & Johnson, contribute to the Buy rating.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, X4 Pharmaceuticals, and ImmunoPrecise Antibodies. According to TipRanks, Ramakanth has an average return of -0.1% and a 34.93% success rate on recommended stocks.